Drug Type Antibody |
Synonyms SARS/COVID-19 Pan-SARS (Inhalon), IN 007, IN007 |
Target |
Mechanism SARS-CoV-2 antigen inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Preclinical | US | 01 Oct 2024 | |
Severe Acute Respiratory Syndrome | Preclinical | US | 01 Oct 2024 |